Teriflunomide - Sanofi Genzyme

Drug Profile

Teriflunomide - Sanofi Genzyme

Alternative Names: A-77-1726; Aubagio; AVE-1726; HMR-1726; HMR1726D; RS-61980; SU-0020

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Genzyme Corporation; Sanofi; Sanofi Genzyme
  • Class Antirheumatics; Hydroxybutyrates; Nitriles; Small molecules; Toluidines
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 25 Oct 2017 Efficacy data from a phase II extension trial in Multiple sclerosis presented at the 7th joint ECTRIMS-ACTRIMS meeting (ECTRIMS-ACTRIMS-2017)
  • 25 Sep 2017 Sanofi initiates enrolment in the phase III TERIS trial for Multiple sclerosis in France (PO) (NCT03122652)
  • 25 Apr 2017 Efficacy and adverse events data from an extension of the phase III TOPIC trial in Multiple sclerosis released by Sanofi Genzyme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top